CytoDyn Inc.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CytoDyn, Inc. is a clinical-stage biotechnology company, which focuses on the clinical development of innovative treatments for multiple therapeutic indications based on its product candidate, leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5. Its pipeline includes Leronlimab Clinical Development Pipeline and Long-Acting CCR5 Inhibitor Development Pipeline. The company was founded by Allen D. Allen on May 2, 2002 and is headquartered in Vancouver, WA.

Ampio Pharmaceuticals Inc

Galectin Therapeutics

Gilead Sciences

Roche Holding AG

Finding The Kink In COVID-19's Armor - Preventing ARDS

CytoDyn's Leronlimab In COVID-19: Debunking The Short Thesis

CytoDyn (CYDY) treats first patient in a phase IIb/III study evaluating leronlimab in severe and critically ill COVID-19 patients. A phase II study on leronlimab shows encouraging results in mild-to-moderate COVID-19 patients.

CytoDyn's Leronlimab Progressing Well in Coronavirus Program

CytoDyn: Understanding The COVID-19 Opportunity

CytoDyn Inc. CYDY, +90.51% said Tuesday the Food and Drug Administration has allowed the company's Phase 2 trial testing its experimental drug leronlimab in COVID-19 patients to move forward.

CytoDyn moves forward with mid-stage trial for experimental COVID-19 treatment

CytoDyn May Be One Of The First Biotechs To Have A Drug That Helps Against Covid-19

CytoDyn: Leronlimab Deployed To The Frontlines Against Coronavirus

CytoDyn: Buy, Sell, Or Hold Following PRO 140 Commercial Agreement

CytoDyn's Future Is Looking Brighter And Brighter: Entering A Transformational Year 2020

News for CytoDyn Inc. Stock (CYDY)